Live attenuated Oka strain of varicella-zoster virus not <103.3 plaque-forming units (PFU)
Indications/Uses
Active immunisation against varicella of healthy subjects from 12 mth onwards, susceptible high-risk patients & their susceptible healthy close contacts.
View Varilrix overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to neomycin or after previous inj. Postpone vaccination in patients w/ acute severe febrile illness. Severe humoral or cellular immunodeficiency eg, patients w/ primary or acquired immunodeficiency states (total lymphocyte count <1,200/mm3); lack of cellular immune competence eg, leukaemia, lymphoma, blood dyscrasias, clinically manifest HIV infection; receiving immunosuppressants. Avoid pregnancy 1 mth after vaccination.
Anaphylactic reactions. Not to be administered intravascularly or intradermally. Syncope. Immunocompromised patients. Allow alcohol & other disinfecting agents to evaporate from skin prior to inj. Women of childbearing potential. Not to be used during pregnancy. Lactation.
Temporary depression of tuberculin skin sensitivity. Delay vaccination at least 3 mth in patients who have received immune globulins or blood transfusion. Reye's syndrome w/ salicylates. Short lived suppression of cell mediated immune response w/ measles vaccine. Not to be administered at the same time w/ other live attenuated vaccines.
Sign Out
